Who is sponsoring NCT03246555?

NCT03246555 is sponsored by Boryung Pharmaceutical Co., Ltd.

What drugs are being tested in NCT03246555?

Interventions in NCT03246555: Fimasartan or Fimasartan/Hydrochlorothiazide, Perindopril or Perindopril/Indapamide.

What condition does NCT03246555 study?

NCT03246555 studies The Elderly (≥ 70 Years) With Essential Hypertension.

Is NCT03246555 still recruiting?

NCT03246555 is currently completed. Last updated 23 March 2020.

Last reviewed 2020-03-23 · How we verify

NCT03246555: FITNESS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fimasartan in the Senior Subjects

Completed Phase 3 Last updated 23 March 2020

What this trial tests

Phase 3 trial testing Fimasartan or Fimasartan/Hydrochlorothiazide in The Elderly (≥ 70 Years) With Essential Hypertension in 241 participants. Completed in 9 December 2019.

Timeline

15 July 2016

Primary endpoint
19 August 2019

9 December 2019

Quick facts

Lead sponsor	Boryung Pharmaceutical Co., Ltd
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	241
Start date	15 July 2016
Primary completion	19 August 2019
Estimated completion	9 December 2019
Sites	1 location across South Korea

Drugs / interventions tested

Fimasartan or Fimasartan/Hydrochlorothiazide — full drug profile →
Perindopril or Perindopril/Indapamide — full drug profile →

Conditions studied

The Elderly (≥ 70 Years) With Essential Hypertension — all drugs for The Elderly (≥ 70 Years) With Essential Hypertension →

Sponsor

Boryung Pharmaceutical Co., Ltd — full company profile →

Who can join

70 and older, any sex, with The Elderly (≥ 70 Years) With Essential Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to confirm the noninferiority of the blood pressure lowering effect of fimasartan and evaluate its safety compared to perindopril in the elderly with essential hypertension.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
Kang MG, Kim KI, Ihm SH, Rhee MY, et al · · 2019 · cited 3× · PMID 31262348 · DOI 10.1186/s13063-019-3466-5
A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hyperte
Lee HY, Kim KI, Ihm SH, Rhee MY, et al · · 2021 · cited 1× · PMID 34503866 · DOI 10.1016/j.clinthera.2021.08.003

Verify or expand the search:

Other Boryung Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

NCT07421414 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421401 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421388 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421375 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07373613 — A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03246555 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boryung Pharmaceutical Co., Ltd
Last refreshed: 23 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03246555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing